CAR-T Cell Therapy Regulatory Considerations: FDA Expectations and Guidance
CAR-T (chimeric antigen receptor T-cell) therapies are regulated by CBER as biological products under Section 351 of the PHS Act, requiring an IND for clinical investigation and a BLA for marketing approval. Key regulatory considerations unique to CAR-T include chain of identity and chain of custody for autologous products, vector characterization, starting-material requirements, release testing under time pressure, and long-term follow-up for products using integrating vectors. As of March 18, 2026, FDA had approved 7 CAR-T products through CBER.
Key Takeaways
Key Takeaways
- CAR-T products are regulated by CBER as biological products under PHS Act Section 351, requiring a BLA for marketing approval
- Chain of identity and chain of custody are critical for autologous CAR-T to ensure the correct patient-specific product is returned to the correct patient
- FDA has used product labeling, postmarketing requirements, and long-term follow-up expectations to manage key CAR-T risks; sponsors should not assume the historical REMS structure remains unchanged for every autologous CAR-T product
- Conditional release based on rapid sterility testing (Gram stain) is standard for autologous CAR-T due to the 14-day USP sterility test exceeding product shelf life
- CAR-T cell therapy presents regulatory challenges that differ from conventional gene therapy and traditional biologics. The product is a living cell, often derived from the patient's own blood (autologous), genetically modified using a viral vector, expanded in culture, and then reinfused. This patient-specific manufacturing chain introduces unique quality, identity, and logistics requirements that have no parallel in other product categories.
- CBER's regulatory framework for CAR-T draws from multiple guidance documents covering gene therapy, cell therapy, and tissue regulations. Understanding how these overlapping frameworks apply to CAR-T products is essential for regulatory strategy development.
- In this guide, you will learn:
- How FDA classifies and regulates CAR-T products
- Autologous vs. allogeneic CAR-T regulatory differences
- Manufacturing chain of identity and chain of custody requirements
- Starting material (leukapheresis) specifications
- Vector characterization and RCL testing
- Release testing requirements and timing challenges
- Clinical trial design considerations for CAR-T
- REMS requirements for approved CAR-T products
- Long-term follow-up obligations
- ---
CAR-T Cell Therapy FDA: Product Classification and Regulatory Framework
CAR-T cell therapy involves genetically modifying a patient's (autologous) or donor's (allogeneic) T cells to express a chimeric antigen receptor (CAR) that directs the T cells to recognize and kill cells expressing a specific target antigen (e.g., CD19 on B-cell malignancies). The CAR construct typically includes an extracellular antigen-binding domain (scFv), a hinge, a transmembrane domain, and intracellular signaling domains (CD3-zeta plus costimulatory domains such as 4-1BB or CD28).
Regulatory Classification
CAR-T products fall under multiple regulatory frameworks simultaneously:
| Framework | Application to CAR-T | Citation |
|---|---|---|
| Biological product | CAR-T is a biologic requiring BLA approval | PHS Act Section 351; 42 U.S.C. 262 |
| Gene therapy product | Uses viral vector for genetic modification | FDA gene therapy guidance documents |
| Cell therapy product | Therapeutic cells are the active agent | 21 CFR Part 1271 (HCT/P framework, but CAR-T exceeds 361 criteria) |
| Somatic cell therapy | Ex vivo manipulation of somatic cells | 21 CFR 1271.3(d) definition |
CAR-T products are regulated as biological products under Section 351 because they involve more than minimal manipulation (genetic modification) and are not used for homologous function (T cells are modified to express a non-native receptor).
CBER Review Division
CBER's Office of Therapeutic Products (OTP) reviews CAR-T applications. Specific divisions within OTP may handle different aspects:
| Review Area | CBER Division |
|---|---|
| Clinical review | Division of Clinical Evaluation (within OTP) |
| CMC review | Division of Product Quality (within OTP) |
| Nonclinical review | Division of Applied Regulatory Science (within OTP) |
CAR-T Regulatory Pathway: Autologous vs. Allogeneic
Autologous CAR-T
In autologous CAR-T, each patient's own T cells are collected, modified, and reinfused. This creates a unique set of regulatory challenges.
| Aspect | Regulatory Implication |
|---|---|
| Patient-specific product | Each lot is a single-patient batch; no batch-to-batch consistency across patients |
| Starting material variability | T-cell quality varies by patient (age, prior treatment, disease burden) |
| Chain of identity | Must ensure the correct product goes back to the correct patient |
| Manufacturing timeline | Typically 2-4 weeks; time-sensitive for patients with progressive disease |
| Shipping logistics | Cryopreserved cells must maintain cold chain from collection to infusion |
| Out-of-specification results | Each lot is unique; no replacement from inventory |
Allogeneic CAR-T
Allogeneic (off-the-shelf) CAR-T uses donor T cells, presenting different regulatory considerations.
| Aspect | Regulatory Implication |
|---|---|
| Donor-derived product | Must meet donor eligibility requirements under 21 CFR 1271 Subpart C |
| Batch manufacturing | Multiple doses from one production run; traditional batch release applicable |
| Graft-versus-host disease | Gene editing to remove TCR reduces GVHD risk; adds gene editing regulatory layer |
| Immune rejection | Host immune response to allogeneic cells; limited persistence |
| Gene editing | CRISPR/TALEN knockout of endogenous TCR and HLA; off-target assessment required |
| Scalability | More conventional manufacturing, but gene editing adds complexity |
Regulatory Comparison
| Requirement | Autologous | Allogeneic |
|---|---|---|
| Donor eligibility (21 CFR 1271 Subpart C) | Not applicable (patient is donor and recipient) | Required |
| Chain of identity | Critical | Standard batch tracking |
| Lot release | Per-patient lot | Standard batch release |
| Potency assay | Must accommodate starting material variability | Standard potency assay |
| Specifications | May require wider acceptance criteria | Standard specification approach |
| Process validation | Challenging (single-patient lots); process characterization approach | Standard process validation (3+ lots) |
| Stability | Product-specific stability on representative lots | Standard stability program |
All 7 FDA-approved CAR-T products as of March 2026 are autologous. Multiple allogeneic CAR-T candidates are in clinical development, but none have yet received BLA approval. The regulatory pathway for allogeneic products combines elements of cell therapy, gene therapy, and gene editing regulatory frameworks.
CAR-T Manufacturing Requirements: Chain of Identity and Custody
Chain of Identity (COI)
Chain of identity is the process that ensures a patient's cells are correctly identified, tracked through manufacturing, and returned to the correct patient. A chain of identity failure is one of the most serious risks in autologous cell therapy.
| COI Element | Requirement |
|---|---|
| Patient identification | Unique patient identifier assigned at enrollment; verified at collection |
| Collection labeling | Leukapheresis product labeled with patient ID before shipping |
| Receipt verification | Manufacturing site verifies patient ID upon receipt |
| In-process tracking | Patient ID maintained on all vessels, bags, and records throughout manufacturing |
| Final product labeling | Patient-specific label with patient ID, product name, lot number |
| Shipping verification | Final product shipped to correct treatment center; verified upon receipt |
| Pre-infusion verification | Two-person verification of patient identity and product label before infusion |
Chain of Custody (COC)
| COC Element | Requirement |
|---|---|
| Temperature monitoring | Continuous temperature monitoring during shipping (validated cold chain) |
| Custody documentation | Document every transfer point from collection to infusion |
| Tamper-evident packaging | Shipping containers must be tamper-evident |
| Receipt confirmation | Each custody transfer confirmed and documented |
| Time limits | Maximum allowable time at each stage defined and monitored |
Starting Material Requirements
The starting material for autologous CAR-T is the patient's leukapheresis product.
| Starting Material Attribute | Specification | Rationale |
|---|---|---|
| T-cell count | Minimum viable T cells per collection | Ensure sufficient cells for manufacturing |
| Viability | Minimum % viable cells | Dead cells do not expand |
| Sterility | No microbial contamination | Patient safety |
| Tumor cell contamination | Assess and minimize | Risk of transducing tumor cells with CAR |
| T-cell subsets | CD4/CD8 ratio, naive/memory phenotype | Affects product quality and potency |
| Prior treatment effects | Document prior therapies (lymphodepleting, checkpoint, etc.) | Prior treatment affects T-cell fitness |
Establish clear acceptance criteria for leukapheresis starting material and define a process for handling out-of-specification collections. Some patients, particularly those heavily pretreated, may not provide starting material meeting standard criteria. Define in the IND whether manufacturing will proceed with suboptimal starting material and what additional release testing or clinical monitoring will apply. FDA expects a documented decision framework for these scenarios.
Vector Characterization and RCL Testing for CAR-T
Viral Vector for CAR-T Manufacturing
Most approved CAR-T products use lentiviral vectors for genetic modification. Retroviral (gamma-retroviral) vectors are used in some products (e.g., Tecartus).
| Vector Attribute | Testing Required |
|---|---|
| Vector identity | Restriction enzyme mapping, transgene sequencing |
| Vector titer | Functional titer (transduction units/mL), physical titer (p24 for lentiviral) |
| Purity | Residual host cell protein, residual DNA, residual plasmid DNA |
| Sterility | 21 CFR 610.12 |
| Mycoplasma | USP <63> |
| Endotoxin | USP <85>, limit per 21 CFR 610.13 |
| RCL | Replication competent lentivirus testing |
RCL Testing Requirements
| Testing Point | Sample | Assay |
|---|---|---|
| Vector lot | Aliquot of final vector product | p24 ELISA, VSV-G PCR, gag/pol PCR, indicator cell assay |
| End-of-production cells | Producer cells at harvest | p24 ELISA, amplification assay |
| Patient-derived product (each lot) | Aliquot of final CAR-T product or retained cells | PCR-based assay for VSV-G (if VSV-G pseudotyped lentiviral vector used) |
| Patient samples (clinical) | Patient blood samples at defined intervals | Archive for retrospective testing per FDA guidance |
Release Testing for CAR-T Products
Release testing for autologous CAR-T products faces a unique challenge: the product has a limited shelf life and the patient may be clinically deteriorating while testing is performed.
Release Testing Panel
| Test | Method | Specification Example | Timing Challenge |
|---|---|---|---|
| Identity | Flow cytometry (CD3+, CAR+) | > X% CD3+CAR+ cells | Results in hours |
| Viability | Trypan blue or flow cytometry | > 70% viable | Results in hours |
| Potency | Cytotoxicity assay (4-hour or overnight killing), cytokine release (IFN-gamma, IL-2) | > X% specific killing at E:T ratio | 4-24 hours |
| Sterility | BacT/ALERT or USP <71> | No growth at 14 days | 14-day incubation exceeds product shelf life |
| Mycoplasma | qPCR (rapid) or culture (USP <63>) | Negative | qPCR: hours; culture: 28 days |
| Endotoxin | LAL (USP <85>) | < 5 EU/kg/hour | Results in hours |
| Cell dose | Cell count | Within specified range per kg body weight | Results in hours |
| RCL | PCR or p24 | Negative | Results in days |
| CAR expression | Flow cytometry | > X% transduction efficiency | Results in hours |
| T-cell phenotype | Flow cytometry (CD4, CD8, memory markers) | For information; may not be release criterion | Results in hours |
| Residual vector | qPCR for vector sequences | Below limit | Results in days |
The Sterility Testing Challenge
The 14-day USP <71> sterility test cannot be completed before product infusion for most CAR-T products with limited shelf life. FDA has addressed this through:
| Approach | Description |
|---|---|
| Gram stain | Rapid (1 hour) interim assessment; not a replacement for sterility but allows infusion to proceed |
| BacT/ALERT inoculation | Inoculate at final product; allow infusion after negative Gram stain; continue incubation to 14 days |
| Conditional release | Product released based on rapid tests; full sterility result available post-infusion |
| Post-infusion positive result | SOPs must define clinical management if sterility test turns positive after infusion |
All approved autologous CAR-T products use conditional release based on rapid sterility methods (Gram stain) combined with concurrent 14-day sterility testing. If the 14-day sterility test returns positive after infusion, the treating physician must be notified immediately and the patient managed per the clinical protocol's infection management plan.
Clinical Trial Design Considerations for CAR-T
Dose Selection and Escalation
| Consideration | CAR-T-Specific Approach |
|---|---|
| Dose unit | CAR+ T cells per kg body weight (or flat dose) |
| Starting dose | Based on nonclinical data and published clinical experience with similar constructs |
| Escalation design | Modified 3+3, Bayesian optimal interval, or continual reassessment |
| DLT window | Typically 28-42 days; must capture CRS and neurotoxicity |
| DLT definition | Grade 3+ CRS not responding to management, Grade 3+ neurotoxicity, other Grade 4+ non-hematologic toxicity |
Lymphodepleting Chemotherapy
Most CAR-T protocols require lymphodepleting chemotherapy before CAR-T infusion.
| Element | Standard Approach |
|---|---|
| Purpose | Create immunologic space for CAR-T expansion; remove regulatory T cells |
| Common regimens | Fludarabine + cyclophosphamide (most common); cyclophosphamide alone; bendamustine |
| Timing | Typically 3-5 days before CAR-T infusion |
| Regulatory consideration | Lymphodepletion is part of the treatment regimen and must be specified in the IND protocol |
Safety Monitoring: CRS and Neurotoxicity
| Adverse Event | Grading System | Monitoring | Management |
|---|---|---|---|
| Cytokine Release Syndrome (CRS) | ASTCT Consensus Grading (Lee 2019) | Vital signs Q4-6h, CRP, ferritin, IL-6 levels | Tocilizumab (Grade 2+), corticosteroids (refractory) |
| Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) | ASTCT ICE score | Neurological assessment Q8-12h during risk period | Corticosteroids (Grade 2+), seizure prophylaxis |
| Hemophagocytic lymphohistiocytosis (HLH)/MAS | HLH criteria | Ferritin, triglycerides, fibrinogen, LDH | Aggressive immunosuppression |
| Prolonged cytopenias | CTCAE grading | CBC monitoring for 3+ months | Growth factor support, transfusions |
| B-cell aplasia | Laboratory monitoring | Immunoglobulin levels | IVIG replacement |
REMS and Postmarketing Risk Controls
CAR-T risk controls have evolved. FDA historically required REMS for autologous CAR-T products because of CRS and neurologic toxicities, but in 2025 FDA modified the REMS burden and removed REMS for the autologous CAR-T products listed in its safety communication, concluding that the risks could be conveyed adequately through labeling and other controls.
REMS Elements for CAR-T
| REMS Element | Requirement |
|---|---|
| Site readiness | Centers still need processes to recognize and manage CRS and neurologic toxicities |
| On-site tocilizumab access | Product-specific requirements and labeling should be checked before infusion |
| Postmarketing safety reporting | 21 CFR 600.80 adverse-event reporting continues to apply |
| Labeling controls | Boxed warnings, medication guides, and product labeling remain central risk-communication tools |
REMS Certification Process
| Step | Action |
|---|---|
| 1 | Review the current product label and any current REMS status in REMS@FDA |
| 2 | Confirm site capability for CRS and ICANS recognition and management |
| 3 | Confirm product-specific requirements for tocilizumab availability and treatment-center readiness |
| 4 | Maintain pharmacovigilance and postmarketing reporting processes |
When planning postmarketing risk controls for a CAR-T program, start from the current labels, REMS@FDA status, and recent FDA safety communications rather than assuming every approved CAR-T still uses the same REMS architecture.
Long-Term Follow-Up for CAR-T
LTFU Requirements
CAR-T products using integrating viral vectors (lentiviral, retroviral) require 15-year long-term follow-up per FDA guidance.
| Monitoring Year | Frequency | Assessments |
|---|---|---|
| Years 1-5 | Semi-annual or annual | Physical exam, CBC with differential, malignancy screening, CAR-T persistence (flow cytometry/qPCR), B-cell recovery, immunoglobulin levels |
| Years 6-15 | Annual | Physical exam, CBC, malignancy screening, adverse event questionnaire |
Secondary Malignancy Monitoring
FDA has placed particular emphasis on secondary malignancy surveillance for CAR-T products following reports of T-cell lymphoma in patients who received CAR-T therapy.
| Event | FDA Action |
|---|---|
| November 2023 | FDA announced investigation of T-cell malignancies in CAR-T recipients |
| January 2024 | FDA required updated labeling for all approved CAR-T products to include boxed warning about T-cell malignancy risk |
| Ongoing | FDA requires manufacturers to report all cases of secondary malignancies, including T-cell lymphomas |
As of FDA's January 2024 communication, 22 cases of T-cell malignancy (including CAR-positive T-cell lymphomas) had been reported among patients treated with approved CAR-T products. While the overall incidence is low relative to the approximately 34,000 patients treated with CAR-T products through that date, FDA determined the risk warranted a class-wide boxed warning and enhanced post-marketing surveillance.
References
As of March 2026, FDA has approved 7 CAR-T products: Kymriah (tisagenlecleucel, 2017), Yescarta (axicabtagene ciloleucel, 2017), Tecartus (brexucabtagene autoleucel, 2020), Breyanzi (lisocabtagene maraleucel, 2021), Abecma (idecabtagene vicleucel, 2021), Carvykti (ciltacabtagene autoleucel, 2022), and Aucatzyl (obecabtagene autoleucel, 2024). All target hematologic malignancies (B-cell lymphomas, B-ALL, multiple myeloma).